Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00218595
Status:
COMPLETED
Last Update Posted:
2014-08-01
First Post:
2005-09-20
Brief Title:
DBT Compared to IGDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Patients - 1
Sponsor:
Duke University
Organization:
Duke University
Study Overview
Official Title:
Evaluation of Dialectical Behavior Therapy in Treatment of Opioid Addiction and Emotional Problems
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the efficacy of DBT compared to a standard drug counseling approach for the treatment of opiate addiction and borderline personality disorder BPD Treatment research has repeatedly shown that retention of BPD and substance addicted individuals to be the among the most challenging for therapists DBT has established itself as one of the most effective treatments for treatment retention of these patients and for reducing parasuicidal and self-injurious behaviors
This study is one of two in a multi-site RCT for the treatment of opiate addiction DBT has been shown to be efficacious for the treatment of BPD patients and it has been extended in this study to target addictive behaviors in these patients The study consists of three treatment parts weekly individual and group therapy and suboxone maintenance medication Participants are provided therapy on a weekly basis for one year and suboxone for 2 years Assessments for tracking outcome are conducted every 4 months
It is hypothesized patients in the DBT condition will show a reduction of substance use parasuicidal and other psychological difficulties and these gains will be maintained through the year of follow-up assessments In addition it is predicted that adherence to DBT treatment protocols will be associated with improved outcomes Finally it is predicted that treatment dosage average hours of therapyweek will be positively related to clinical improvement
This study is one of two in a multi-site RCT for the treatment of opiate addiction DBT has been shown to be efficacious for the treatment of BPD patients and it has been extended in this study to target addictive behaviors in these patients The study consists of three treatment parts weekly individual and group therapy and suboxone maintenance medication Participants are provided therapy on a weekly basis for one year and suboxone for 2 years Assessments for tracking outcome are conducted every 4 months
It is hypothesized patients in the DBT condition will show a reduction of substance use parasuicidal and other psychological difficulties and these gains will be maintained through the year of follow-up assessments In addition it is predicted that adherence to DBT treatment protocols will be associated with improved outcomes Finally it is predicted that treatment dosage average hours of therapyweek will be positively related to clinical improvement
Detailed Description:
The study design is a two arm randomized clinical trial comparing a one year treatment program of Dialectical Behavior Therapy DBT suboxone for heroin addicted individuals meeting criteria for borderline personality disorder BPD to a one year program of standard drug counseling IGDC suboxone Drug counseling will consist of manualized individual sessions group therapy Participants in both conditions will be prescribed psychotropic medications following a standardized medication protocol developed specifically for BPD individuals Each site will enroll 86 clients with both treatment conditions being conducted at each site Assessments measuring drug use suicidal behaviors retention and other treatment-related behaviors general psychopathology and functioning and increases in behavioral skills will be given at four month intervals for two years
There are five outcome domains of principal interest in this study
1 Drug use The primary outcome measure here is proportions of urinalysis UA coded positive for opiates
2 Suicidal behaviors The primary outcome measure here is number of suicides suicide attempts The domain of suicidal behaviors also includes a the number medical risk riskrescue score and suicide intent of all parasuicide b the number of suicide threats and suicide crises and c the level of suicidal ideation and suicide intent
3 Therapy-interfering behaviors The primary outcome measure here is maintenance in therapy
4 Quality of life interfering behaviors The primary outcome measure here is combined number of days on a psychiatric inpatient unit days in jail THI SHI
5 Behavioral skills The primary outcome measure here is the DBT Skills scale score from the Revised Ways of Coping Checklist RWCCL
6 Risky sexual behavior the primary outcome measure here is the number of risky sexual behaviors in the time period Casual Partners questionnaire revised CPQ-R and diary card
There are five outcome domains of principal interest in this study
1 Drug use The primary outcome measure here is proportions of urinalysis UA coded positive for opiates
2 Suicidal behaviors The primary outcome measure here is number of suicides suicide attempts The domain of suicidal behaviors also includes a the number medical risk riskrescue score and suicide intent of all parasuicide b the number of suicide threats and suicide crises and c the level of suicidal ideation and suicide intent
3 Therapy-interfering behaviors The primary outcome measure here is maintenance in therapy
4 Quality of life interfering behaviors The primary outcome measure here is combined number of days on a psychiatric inpatient unit days in jail THI SHI
5 Behavioral skills The primary outcome measure here is the DBT Skills scale score from the Revised Ways of Coping Checklist RWCCL
6 Risky sexual behavior the primary outcome measure here is the number of risky sexual behaviors in the time period Casual Partners questionnaire revised CPQ-R and diary card
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 5R01DA026454-03 | NIH | None | None |
| R01-17372-1 | US NIH GrantContract | None | httpsreporternihgovquickSearch5R01DA026454-03 |